rTMS for clozapine refractory schizophrenia – A systematic review and pairwise meta-analysis
| Autor: | Surabhi Sinha, Faraz Honarparvar, Dan Siskind, Stacy Orr, Steve Kisely, Elias Wagner, Alkomiet Hasan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Population behavioral disciplines and activities 03 medical and health sciences 0302 clinical medicine mental disorders medicine Humans Treatment Failure education Antipsychotic Psychiatry Clozapine Biological Psychiatry Temporal cortex education.field_of_study business.industry medicine.disease Transcranial Magnetic Stimulation 030227 psychiatry Transcranial magnetic stimulation Psychiatry and Mental health medicine.anatomical_structure Schizophrenia Scalp Meta-analysis business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Schizophrenia Research. 211:113-114 |
| ISSN: | 0920-9964 |
| DOI: | 10.1016/j.schres.2019.07.004 |
| Popis: | Dear Editor, Only 40% of people with treatment refractory schizophrenia will respond to clozapine (Siskind et al., 2017), even though is the most effective antipsychotic for this population (Land et al., 2017; Siskind et al., 2016). There is limited evidence for pharmacological augmentation of clozapine (Siskind et al., 2018; Wagner et al., 2019a). By contrast, non-pharmacological strategies such as repetitive transcranial magnetic stimulation (rTMS), defined as repetitive application of magnetic pulses through the scalp targeting the prefrontal or temporal cortex, may hold promise. Among people with schizophrenia on any antipsychotic, rTMS can reduce both auditory hallucinations and negative symptoms, with a substantial heterogeneity across trials (Kennedy et al., 2018). A recent sub-analysis of rTMS for people with predominant negative symptoms of schizophrenia on clozapine found reductions in total and positive psychotic symptoms (Wagner et al., 2019b). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect